Emilia Development: What Eroded Chemobile's Profitability

Where Chemobile Really Broke

This follow-up stays tightly on the weak point in Emilia Development's 2025 cycle. The issue was not a single shock. It was a stack of pressures: lower selling prices in part of the portfolio, a weaker dollar against the shekel, the disappearance of unique 2024 projects, acquisitions that added revenue but did not protect margin, and a working-capital and financing structure that turned a moderate revenue decline into a much sharper profit hit.

That gap is the core of the story. Chemobile's revenue fell only 3.3% in 2025 to NIS 697.0 million, but gross profit dropped 14.5% to NIS 119.8 million, operating profit was cut 50.8% to NIS 26.7 million, and pre-tax profit collapsed 77.8% to NIS 9.3 million. This was not just a volume problem. It was a deterioration in revenue quality and in the segment's ability to convert turnover into profit.

The Damage Started With Pricing and the Comparison Base

The filing explicitly says the 2025 revenue decline was driven in part by lower selling prices in some products, including pressure linked to the dollar's weakness against the shekel. That matters because it means the erosion began in price, before financing or overhead enter the picture. In a segment built partly on imported raw materials and distribution, FX is not a footnote. It affects pricing, repricing speed, and the lag between cost and recovery.

There is also a less obvious point in the filing: 2024 was not a clean base year. The company says part of the prior-year revenue came from unique projects that did not continue into 2025. So this is not simply a weak year against a normal year. It is a year with price pressure and a tougher comparison base than the headline revenue line suggests.

What stands out is that the company's explanation does not rely on a lost customer or on a single demand shock. It relies on price pressure and on projects that did not recur. That explains how a roughly NIS 24 million revenue decline can still translate into more than NIS 20 million of lost gross profit and more than NIS 27 million of lost operating profit. When revenue weakens on price rather than volume, margin erodes faster than sales.

There is also a clue in the commercial mix. The share of Chemobile revenue generated under tenders or framework agreements fell to 22% in 2025 from 30% in 2024. That does not prove contract mix alone caused the margin decline, but it does mean a larger share of activity sat in shorter-cycle orders and was more exposed to current market pricing and changing commercial terms.

Bolt-On Acquisitions Supported Revenue, Not Margin

The company says the revenue decline was partly offset by newly acquired activities. That matters because without those deals the top line would likely have looked weaker. The relevant sections in the filing point to two meaningful moves around the period: the micro-minerals and metals activity acquired from Koy, and the hospital-disinfection activity acquired from Ronli and completed in March 2025. By contrast, the Universal food-ingredients acquisition was signed only in October 2025 and completed in March 2026, so it could not rescue 2025 results.

The implication is that the bolt-ons worked first at the volume layer. They helped soften the revenue decline, but they did not prevent margin erosion. If revenue still fell even after added activity, and gross margin still dropped to 17.2% from 19.5%, then the weakness in the core business was deeper than the acquisition contribution.

That is why 2025 cannot be read as a pure one-off. If the problem were only the absence of a specific project, acquisitions should have absorbed a bigger part of the damage. Instead, they provided only partial protection. In other words, the deals helped fill the revenue pipe, but they have not yet proved that they improve Chemobile's profit quality.

Financing Turned an Operating Problem Into a Much Deeper Earnings Hit

Chemobile weakened at the operating line, but the bottom-line damage became much worse because financing moved against it. Segment net finance expense rose to NIS 17.4 million from NIS 12.4 million. In the directors' report, the company attributes that increase mainly to FX losses and higher finance expense on leases. That is a critical point. It means the erosion did not stop at gross margin. It continued below operating profit.

This is where working capital becomes part of the same story. On one level, the picture improved: customer days fell to 107 from 120, and working capital dropped to NIS 107.0 million from NIS 128.1 million. But this is still a cash-hungry business. Inventory days rose to 92 from 88, supplier days were only 59, and the filing adds that a significant part of imports, mainly from East Asia, is paid by bank transfer before the goods are prepared abroad and before they are shipped to Israel. So even with better collection days, the business model still requires meaningful upfront cash support.

In cash-cycle terms, the business still sits around roughly 140 operating working-capital days. That is better than roughly 150 days in 2024, but it is still demanding enough to explain why pricing and FX pressure translate quickly into financing pressure. The business is not only earning less on each shekel of revenue. It also has to keep funding inventory, receivables, and imported materials paid for in advance.

The debt structure also became less simple. At year-end 2025, Chemobile had roughly NIS 147.5 million of bank debt, including about NIS 66.0 million of non-linked debt, NIS 56.4 million of CPI-linked debt, and NIS 25.0 million of dollar-linked debt. In 2024 the mix was much more heavily non-linked. That does not mean Chemobile lost control of the balance sheet, but it does mean the finance line became more sensitive than it may first appear to a combination of indexation, FX, and rates.

The Fourth Quarter Showed a Hint, Not a Solution

The relatively constructive point is that late in the year there was an early sign of operational improvement. In the fourth quarter, Chemobile revenue fell only 2.3% to NIS 170.2 million, but gross profit actually rose 9.7% to NIS 28.6 million, and gross margin improved to 16.8% from 14.9%. The directors' report attributes that, among other things, to operational efficiency measures and to roughly NIS 3 million lower G&A expense at Chemobile.

But that hint did not become a full fix. In the fourth quarter, net finance expense rose to NIS 4.0 million from NIS 2.2 million, and pre-tax profit moved from a NIS 4.5 million profit to a NIS 0.9 million loss. So at the operating-core level there is an early sign of stabilization, but at this stage it is still not enough to absorb the drag coming from financing and other charges.

That matters because it prevents an overly blunt read of 2025. If you look only at the full-year figures, the conclusion looks settled. In practice, year-end offers an early sign of partial operating stabilization. For now, though, that stabilization is still being absorbed by a working-capital and financing structure that keeps demanding too much from the bottom line.

Conclusion

Chemobile's 2025 margin erosion did not come from one event. It came from the overlap of four forces: weaker pricing in part of the portfolio, a weaker dollar against the shekel, the disappearance of one-off 2024 projects, and a funding and working-capital structure that magnified the damage. Acquisitions helped soften the revenue decline, but they did not protect profitability.

The reasonable counter-argument is that 2025 was mostly a noise-cleaning year: a hard comparison base, FX turbulence, and a fourth quarter that already showed operational improvement. That is a serious argument, but it still needs proof. Until the company shows that gross margin can hold at a better level, that acquisitions add profit and not only volume, and that financing stops absorbing the operating improvement, Chemobile remains the main friction point inside the Emilia Development story.